AURX Nuo Therapeutics, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1091596 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY123.7%
TTM net income YoY2.0%
TTM EPS YoY—
Revenue 3-yr CAGR308.7%
Net income 3-yr CAGR—
Margins
Gross margin70.4%
Operating margin-98.3%
Net margin-93.1%
FCF margin-44.6%
EBITDA margin-95.5%
Returns
ROE-1,032.5%
ROA-133.3%
ROIC (approx.)—
Asset turnover1.43x
Leverage & solvency
Liabilities / assets121.8%
Debt / equity—
Current ratio1.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio-82.1%
Payout ratio—
Capex / revenue8.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.87M | $1.77M | $1.30M | $1.10M | $1.03M | $700,202 | $484,381 | $394,872 |
| Cost of revenue | $673,334 | $598,959 | $452,388 | $408,461 | $406,721 | $159,350 | $121,021 | $86,412 |
| Gross profit | $1.19M | $1.17M | $849,727 | $688,369 | $625,375 | $540,852 | $363,360 | $308,460 |
| SG&A expense | $1.57M | $1.34M | $1.30M | $1.27M | $1.17M | $1.19M | $1.11M | $937,694 |
| Operating income | -$374,432 | -$166,552 | -$446,466 | -$579,338 | -$540,142 | -$652,022 | -$745,147 | -$629,234 |
| Net income | -$424,928 | -$277,601 | -$618,466 | -$578,480 | -$537,919 | -$649,689 | -$746,128 | -$496,666 |
| EBITDA | -$373,820 | -$140,354 | -$424,210 | -$555,426 | -$516,994 | -$628,966 | -$729,800 | -$617,718 |
| EPS (basic) | -0.01 | -0.01 | -0.01 | — | -0.01 | -0.01 | -0.02 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $80,941 | $449,325 | $263,827 | $548,946 | $514,797 | $316,354 | $55,655 | $283,714 |
| Receivables | $1.41M | $1.17M | $873,669 | $561,667 | $652,252 | $320,440 | $276,532 | $248,205 |
| Inventory | $330,134 | $269,518 | $248,537 | $213,761 | $201,627 | $165,816 | $99,173 | $150,442 |
| Current assets | $1.98M | $1.99M | $1.52M | $1.38M | $1.46M | $853,280 | $601,506 | $841,546 |
| PP&E, net | $704,903 | $571,735 | $344,906 | $366,315 | $347,022 | $370,170 | $391,559 | $177,022 |
| Total assets | $2.73M | $2.63M | $1.95M | $1.85M | $1.93M | $1.36M | $1.15M | $1.19M |
| Current liabilities | $2.45M | $1.55M | $1.37M | $1.31M | $1.26M | $998,955 | $1.28M | $578,451 |
| Total liabilities | $4.58M | $4.16M | $3.33M | $2.80M | $2.35M | $2.18M | $1.36M | $675,796 |
| Shareholders' equity | -$1.85M | -$1.54M | -$1.38M | -$956,559 | -$419,606 | -$824,561 | -$213,073 | $513,712 |
| Shares outstanding | 48.57M | 48.42M | 48.29M | 48.18M | 47.88M | 46.83M | 46.82M | 46.82M |
| Cash flow statement | ||||||||
| Operating cash flow | -$194,604 | -$236,475 | -$784,272 | -$422,646 | -$706,516 | $262,366 | $1,825 | -$490,539 |
| Capital expenditure | $173,780 | $253,027 | $847 | $43,205 | $0 | $1,667 | $229,884 | $0 |
| Free cash flow | -$368,384 | -$489,502 | -$785,119 | -$465,851 | -$706,516 | $260,699 | -$228,059 | -$490,539 |
| Investing cash flow | -$173,780 | -$253,027 | -$847 | -$43,205 | $0 | -$1,667 | -$229,884 | $0 |
| Financing cash flow | $0 | $675,000 | $500,000 | $500,000 | $904,959 | $0 | $0 | $90,417 |
| Depreciation & amortization | $612 | $26,198 | $22,256 | $23,912 | $23,148 | $23,056 | $15,347 | $11,516 |
| Stock-based compensation | $89,238 | $41,490 | $23,527 | $23,527 | $19,915 | $23,201 | $19,343 | $29,574 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.